What's in Servier Affaires Médicales's pipeline?

Servier Affaires Médicales has 1 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Servier Affaires Médicales's portfolio?

Top competitors by shared drug class: , GRADE Study Group, Italian Society of Diabetology, Janssen Research & Development, LLC, Merck Sharp & Dohme LLC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/servier-affaires-m-dicales.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Servier Affaires Médicales — Portfolio Competitive Intelligence Brief

Servier Affaires Médicales pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Diabetes · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
GRADE Study Group · 1 shared drug class
Italian Society of Diabetology · 1 shared drug class
Janssen Research & Development, LLC · 1 shared drug class
Merck Sharp & Dohme LLC · 1 shared drug class
Pfizer · 1 shared drug class
Samsung Medical Center · 1 shared drug class
Sanofi · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Servier Affaires Médicales:

Cite this brief

Drug Landscape (2026). Servier Affaires Médicales — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/servier-affaires-m-dicales. Accessed 2026-05-16.